vs
Investar Holding Corp(ISTR)与STANDARD BIOTOOLS INC.(LAB)财务数据对比。点击上方公司名可切换其他公司
Investar Holding Corp的季度营收约是STANDARD BIOTOOLS INC.的1.2倍($23.5M vs $19.6M),Investar Holding Corp同比增速更快(0.9% vs -11.5%),过去两年Investar Holding Corp的营收复合增速更高(4.9% vs -12.2%)
Investar Holding Corp是一家总部位于美国的银行控股公司,主要服务墨西哥湾沿岸地区客户,提供全面的商业及零售银行服务,包括存款产品、各类消费及商业贷款、抵押服务和财富管理解决方案,覆盖个人、中小企业及商业客户群体。
Standard BioTools(原Fluidigm公司)是一家美国生命科学工具企业,主营流式细胞术与组织成像分析用质谱流式系统,以及配套的检测试剂盒与试剂,同时供应自动化基因组分析仪器、各类微流控芯片(又称集成流体电路)及配套试剂耗材,全系列产品及应用场景均可提供定制检测方案与相关服务。
ISTR vs LAB — 直观对比
营收规模更大
ISTR
是对方的1.2倍
$19.6M
营收增速更快
ISTR
高出12.3%
-11.5%
两年增速更快
ISTR
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $23.5M | $19.6M |
| 净利润 | — | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | 30.9% | -168.5% |
| 净利率 | — | -177.4% |
| 营收同比 | 0.9% | -11.5% |
| 净利润同比 | — | -28.8% |
| 每股收益(稀释后) | $0.50 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
ISTR
LAB
| Q4 25 | $23.5M | — | ||
| Q3 25 | $24.1M | $19.6M | ||
| Q2 25 | $22.3M | $21.8M | ||
| Q1 25 | $24.0M | $40.8M | ||
| Q4 24 | $23.3M | — | ||
| Q3 24 | $22.3M | $22.1M | ||
| Q2 24 | $20.4M | $22.5M | ||
| Q1 24 | $21.4M | $45.5M |
净利润
ISTR
LAB
| Q4 25 | — | — | ||
| Q3 25 | $6.2M | $-34.7M | ||
| Q2 25 | $4.5M | $-33.5M | ||
| Q1 25 | $6.3M | $-26.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $5.4M | $-26.9M | ||
| Q2 24 | $4.1M | $-45.7M | ||
| Q1 24 | $4.7M | $-32.2M |
毛利率
ISTR
LAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% |
营业利润率
ISTR
LAB
| Q4 25 | 30.9% | — | ||
| Q3 25 | 31.0% | -168.5% | ||
| Q2 25 | 24.4% | -118.1% | ||
| Q1 25 | 32.2% | -80.8% | ||
| Q4 24 | 31.1% | — | ||
| Q3 24 | 27.6% | -120.9% | ||
| Q2 24 | 24.0% | -134.5% | ||
| Q1 24 | 28.5% | -132.2% |
净利率
ISTR
LAB
| Q4 25 | — | — | ||
| Q3 25 | 25.6% | -177.4% | ||
| Q2 25 | 20.2% | -153.7% | ||
| Q1 25 | 26.3% | -63.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 24.1% | -122.0% | ||
| Q2 24 | 19.9% | -203.3% | ||
| Q1 24 | 22.0% | -70.6% |
每股收益(稀释后)
ISTR
LAB
| Q4 25 | $0.50 | — | ||
| Q3 25 | $0.54 | $-0.09 | ||
| Q2 25 | $0.46 | $-0.09 | ||
| Q1 25 | $0.63 | $-0.07 | ||
| Q4 24 | $0.61 | — | ||
| Q3 24 | $0.54 | $-0.07 | ||
| Q2 24 | $0.41 | $-0.12 | ||
| Q1 24 | $0.48 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | — | $129.4M |
| 总债务越低越好 | $9.8M | — |
| 股东权益账面价值 | $301.1M | $399.7M |
| 总资产 | $2.8B | $539.6M |
| 负债/权益比越低杠杆越低 | 0.03× | — |
8季度趋势,按日历期对齐
现金及短期投资
ISTR
LAB
| Q4 25 | — | — | ||
| Q3 25 | — | $129.4M | ||
| Q2 25 | — | $158.6M | ||
| Q1 25 | — | $150.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $210.6M | ||
| Q2 24 | — | $269.8M | ||
| Q1 24 | — | $287.1M |
总债务
ISTR
LAB
| Q4 25 | $9.8M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $9.8M | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益
ISTR
LAB
| Q4 25 | $301.1M | — | ||
| Q3 25 | $295.3M | $399.7M | ||
| Q2 25 | $255.9M | $424.5M | ||
| Q1 25 | $251.7M | $454.6M | ||
| Q4 24 | $241.3M | — | ||
| Q3 24 | $245.5M | $489.3M | ||
| Q2 24 | $230.2M | $510.3M | ||
| Q1 24 | $227.0M | $577.3M |
总资产
ISTR
LAB
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.8B | $539.6M | ||
| Q2 25 | $2.7B | $557.0M | ||
| Q1 25 | $2.7B | $579.6M | ||
| Q4 24 | $2.7B | — | ||
| Q3 24 | $2.8B | $681.5M | ||
| Q2 24 | $2.8B | $708.7M | ||
| Q1 24 | $2.8B | $777.7M |
负债/权益比
ISTR
LAB
| Q4 25 | 0.03× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $18.2M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | — | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势,按日历期对齐
经营现金流
ISTR
LAB
| Q4 25 | $18.2M | — | ||
| Q3 25 | $6.9M | $-22.2M | ||
| Q2 25 | $3.2M | $-20.7M | ||
| Q1 25 | $4.5M | $-30.3M | ||
| Q4 24 | $15.9M | — | ||
| Q3 24 | $5.6M | $-27.9M | ||
| Q2 24 | $2.8M | $-39.0M | ||
| Q1 24 | $7.8M | $-62.5M |
自由现金流
ISTR
LAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | — | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | — | $-63.3M |
自由现金流率
ISTR
LAB
| Q4 25 | — | — | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | — | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | — | -138.9% |
资本支出强度
ISTR
LAB
| Q4 25 | — | — | ||
| Q3 25 | — | 4.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 8.6% | ||
| Q1 24 | — | 1.7% |
现金转化率
ISTR
LAB
| Q4 25 | — | — | ||
| Q3 25 | 1.12× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 1.66× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ISTR
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |